Casdin Capital’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $46M | Buy |
4,095,571
+100,000
| +3% | +$1.12M | 4.19% | 7 |
|
|
2025
Q1 | $18.3M | Hold |
3,995,571
| – | – | 1.49% | 13 |
|
|
2024
Q4 | $22.5M | Hold |
3,995,571
| – | – | 1.5% | 16 |
|
|
2024
Q3 | $19.3M | Buy |
3,995,571
+936,477
| +31% | +$4.53M | 1.29% | 18 |
|
|
2024
Q2 | $14.9M | Hold |
3,059,094
| – | – | 1.14% | 20 |
|
|
2024
Q1 | $40.6M | Buy |
3,059,094
+50,000
| +2% | +$664K | 3.02% | 11 |
|
|
2023
Q4 | $41.9M | Buy |
3,009,094
+54,384
| +2% | +$758K | 4.12% | 8 |
|
|
2023
Q3 | $39.2M | Buy |
2,954,710
+594,139
| +25% | +$7.88M | 4.34% | 7 |
|
|
2023
Q2 | $44.3M | Buy |
2,360,571
+240,000
| +11% | +$4.5M | 3.87% | 9 |
|
|
2023
Q1 | $30.6M | Sell |
2,120,571
-170,000
| -7% | -$2.45M | 2.52% | 13 |
|
|
2022
Q4 | $44.3M | Sell |
2,290,571
-887,596
| -28% | -$17.2M | 3.43% | 10 |
|
|
2022
Q3 | $109M | Buy |
3,178,167
+40,000
| +1% | +$1.37M | 7.17% | 6 |
|
|
2022
Q2 | $48M | Hold |
3,138,167
| – | – | 4.05% | 10 |
|
|
2022
Q1 | $71.6M | Hold |
3,138,167
| – | – | 3.21% | 12 |
|
|
2021
Q4 | $116M | Buy |
3,138,167
+100,000
| +3% | +$3.69M | 3.26% | 14 |
|
|
2021
Q3 | $143M | Hold |
3,038,167
| – | – | 3.55% | 10 |
|
|
2021
Q2 | $183M | Buy |
+3,038,167
| New | +$183M | 4.65% | 5 |
|